Background: It is difficult to predict the risk of falling, especially in patients with good motor ability, and the mechanisms underlying the relation between gait patterns and falling in Parkinson’s disease (PD) remain unclear. We investigated factors related to falling, including walking speed and time, in patients with Hoehn-Yahr stage III PD. Methods: We performed clinical assessments and evaluated balance in 30 patients with PD. Information on falling was obtained from questionnaires and personal interviews. Gait patterns were analyzed with the use of an originally designed, suddenly narrowed path. Results: Gait velocity was slower in fallers than in non-fallers (p = 0.047). Unified Parkinson’s Disease Rating Scale part II (UPDRS part II) score, fear of falling, and gait velocity were significantly related to falling on analysis with a single logistic model. When a multiple logistic model was used, the UPDRS part II score was significantly related to falling (OR: 1.48, p = 0.037, 95% CI: 1.02–2.16). Conclusions: Patients with Hoehn-Yahr stage III PD showed slow gait velocity attributed to fear of falling before arrival at a narrowed entrance or while walking on a narrowed path. The UPDRS part II score is significantly related to the risk of future falls.

1.
Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM: Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384–386.
2.
Pickering RM, Grimbergen YA, Rigney U, Ashburn A, Mazibrada G, Wood B, Gray P, Kerr G, Bloem BR: A meta-analysis of six prospective studies of falling in Parkinson’s disease. Mov Disord 2007;22:1892–1900.
3.
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG: The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837–844.
4.
Kerr GK, Worringham CJ, Cole MH, Lacherez PF, Wood JM, Silburn PA: Predictors of future falls in Parkinson disease. Neurology 2010;75:116–124.
5.
Melton LJ 3rd, Leibson CL, Achenbach SJ, Bower JH, Maraganore DM, Oberg AL, Rocca WA: Fracture risk after the diagnosis of Parkinson’s disease: influence of concomitant dementia. Mov Disord 2006;21:1361–1367.
6.
Lee AC, Harris JP: Problems with perception of space in Parkinson’s disease. Neuroophthalmology 1999;22:1–15.
7.
Hausdorff JM, Schaafsma JD, Balash Y, Bartels AL, Gurevich T, Giladi N: Impaired regulation of stride variability in Parkinson’s disease subjects with freezing of gait. Exp Brain Res 2003;149:187–194.
8.
Almeida QJ, Lebold CA: Freezing of gait in Parkinson’s disease: a perceptual cause for a motor impairment? J Neurol Neurosurg Psychiatry 2010;81:513–518.
9.
Calne DB, Snow BJ, Lee C: Criteria for diagnosing Parkinson’s disease. Ann Neurol 1992;32:S125–S127.
10.
Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33–39.
11.
Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–442.
12.
Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK: Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94–98.
13.
Fahn S, Elton R: Members of UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale; in Fahn S, Marsden CD, Caine DB, Goldstein M (eds): Recent Developments in Parkinson’s Disease. Florham Park, Macmillan Health Care Information, 1987, vol 2, pp 153–163, 293–304.
14.
Minguez-Castellanos A, Escamilla-Sevilla F, Katati MJ, Martin-Linares JM, Meersmans M, Ortega-Moreno A, Arjona V: Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson’s disease: target related effect or selection bias? J Neurol Neurosurg Psychiatry 2005;76:34–39.
15.
Schindehütte J, Trenkwalder C: ‘Atypical anti-psychotics’ are substances of choice in treating drug-induced psychosis (DP) in Parkinson’s disease (PD). Clin Neurol Neurosurg 2007;109:188–191.
16.
Tinetti ME, Speechley M, Ginter SF: Risk factors for falls among elderly persons living in the community. N Engl J Med 1988;319:1701–1707.
17.
Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, Uchitomi Y: Validation study of the Japanese version of the Brief Fatigue Inventory. J Pain Symptom Manage 2003;25:106–117.
18.
Gehlsen GM, Whaley MH: Falls in the elderly: part II, balance, strength, and flexibility. Arch Phys Med Rehabil 1990;71:739–741.
19.
Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff JM, Giladi N: Falls in outpatients with Parkinson’s disease: frequency, impact and identifying factors. J Neurol 2005;252:1310–1315.
20.
Giladi N, Hausdorff JM: The role of mental function in the pathogenesis of freezing of gait in Parkinson’s disease. J Neurol Sci 2006;248:173–176.
21.
Mak MK, Pang MY: Fear of falling is independently associated with recurrent falls in patients with Parkinson’s disease: a 1-year prospective study. J Neurol 2009;256:1689–1695.
22.
Ashburn A, Stack E, Pickering RM, Ward CD: Predicting fallers in a community-based sample of people with Parkinson’s disease. Gerontology 2001;47:277–281.
23.
Adkin AL, Frank JS, Jog MS: Fear of falling and postural control in Parkinson’s disease. Mov Disord 2003;18:496–502.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.